利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.017 秒)

    Solid preparation administering instrument
    1.
    发明授权
    Solid preparation administering instrument 失效
    固体制剂给药仪器

    公开(公告)号：US4900304A

    公开(公告)日：1990-02-13

    申请号：US79429

    申请日：1987-07-30

    申请人： Keiji Fujioka ,  Shigeji Sato ,  Nobuhiko Tamura ,  Yoshihiro Takada ,  Yoshio Sasaki

    发明人： Keiji Fujioka ,  Shigeji Sato ,  Nobuhiko Tamura ,  Yoshihiro Takada ,  Yoshio Sasaki

    IPC分类号： A61M5/00 ,  A61M36/00 ,  A61M36/12 ,  A61M37/00

    CPC分类号： A61M37/0069

    摘要： A device for administering solid or semisolid preparations under the skin, which comprises a solid needle member with an acute tip end, and a cylindrical member slidably mounted on the needle member. The solid needle member having a recess at its front part to form a preparation chamber between the needle member and cylindrical member, and the chamber being opened or closed by moving the cylindrical member in the direction parallel to the axis of the needle member. The device may comprises a cylindrical member with a capsule chamber, a hollow needle member removable mounted on the front end of the cylindrical member, and a plunger slidably arranged in the capsule chamber of the cylindrical member, all of which have a common axis so that the plunger enters into the hollow needle member through the capsule chamber.

    Sustained pulsewise release pharmaceutical preparation
    3.
    发明授权
    Sustained pulsewise release pharmaceutical preparation 失效
    持续脉搏释放药物制剂

    公开(公告)号：US5011692A

    公开(公告)日：1991-04-30

    申请号：US946158

    申请日：1986-12-23

    申请人： Keiji Fujioka ,  Shigeji Sato ,  Yoshihiro Takada ,  Yoshio Sasaki ,  Nobuhiko Tamura

    发明人： Keiji Fujioka ,  Shigeji Sato ,  Yoshihiro Takada ,  Yoshio Sasaki ,  Nobuhiko Tamura

    IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K9/22 ,  A61K9/24 ,  A61K9/70

    CPC分类号： A61K9/2072 ,  A61K9/209

    摘要： The invention relates to sustained pulsewise release pharmaceutical preparation which comprices drug-containing polymeric material layers (layers A) and polymeric material layers containing the drug in question only in a slight amount or free of the drug (layers B) disposed alternatingly, with the whole surface extending in the direction perpendicular to the layer plane being coated with a polymeric material which is insoluble in water or scarcely soluble in water (polymeric material C).This pharmaceutical preparation of this invention is designed so that active ingredients which should desirably be released pulsewise can be released therefrom in a pulse-like and clinically significant manner and thereby the pharmacological effects of said active ingredients can be maintained for a prolonged period of time.

    摘要翻译： 本发明涉及持续的脉搏释放药物制剂，其将含药物的聚合物材料层（层A）和含有所述药物的聚合物材料层仅含有少量或不含交替设置的药物（B层）与整体 表面沿垂直于层平面的方向延伸，涂覆有不溶于水或几乎不溶于水的聚合材料（聚合物C）。 本发明的这种药物制剂被设计成使得脉动式的理想释放的活性成分能以脉冲状和临床显着的方式从其中释放出来，从而可以延长所述活性成分的药理作用。

    Stable growth hormone releasing factor preparation
    8.
    发明授权
    Stable growth hormone releasing factor preparation 失效
    稳定的生长激素释放因子制剂

    公开(公告)号：US4963529A

    公开(公告)日：1990-10-16

    申请号：US168617

    申请日：1988-03-08

    申请人： Keiji Fujioka ,  Shigeji Sato ,  Yoshihiro Takada

    发明人： Keiji Fujioka ,  Shigeji Sato ,  Yoshihiro Takada

    IPC分类号： A61K38/25

    CPC分类号： A61K38/25 ,  Y10S514/97

    摘要： Growth hormone releasing factor (GRF) preparation which is excellent in stablity by having human serum albumin or glycine incorporated therein, with or without buffer. An amount of human serum albumin or glycine contained is usually 100 .mu.g to 30 mg per 100 .mu.g GRF. The preparation may be in the solid or solution form, preferably in the lyophilized form. An amount of buffer, if added, is preferably enough so that pH of the preparation is kept at 2-7. More preference is that the preparation is kept in nitrogen gas atmosphere. The lyophilized preparation is readily usable for, for example, injection.

    摘要翻译： 生长激素释放因子（GRF）制剂，其中含有或不含有缓冲液的人血清白蛋白或甘氨酸是稳定的。 人血清白蛋白或甘氨酸含量通常为100μg至30mg / 100g GRF。 制剂可以是固体或溶液形式，优选为冻干形式。 缓冲液的量如果加入，则优选足以使制剂的pH保持在2-7。 更优选的是将制剂保持在氮气气氛中。 冻干制剂容易用于例如注射。